STOCK TITAN

Biophytis - BPTS STOCK NEWS

Welcome to our dedicated news page for Biophytis (Ticker: BPTS), a resource for investors and traders seeking the latest updates and insights on Biophytis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biophytis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biophytis's position in the market.

Rhea-AI Summary
Biophytis and Skyepharma partner to produce regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19, securing production of finished product batches of leading drug candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
80.66%
Tags
partnership
-
Rhea-AI Summary
Biophytis receives response from French National Authority for Health regarding Early Access Authorization for COVID-19 treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.14%
Tags
covid-19
-
Rhea-AI Summary
Biophytis strengthens management team with new appointments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Rhea-AI Summary
Biophytis receives FDA authorization for SARA-31 study in the US, the first phase 3 study in sarcopenia. The study is scheduled to start in 2024, pending partnership agreements and financial resources. CEO expects growing interest in Sarconeos as a therapeutic response for sarcopenia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
-
Rhea-AI Summary
Biophytis SA CEO to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
conferences
-
Rhea-AI Summary
Biophytis plans next regulatory steps for its COVA project, receives feedback from EMA and FDA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.15%
Tags
none
Rhea-AI Summary
Biophytis receives positive opinion to conduct phase 3 study for sarcopenia treatment; potential market of 30 million patients worldwide
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
-
Rhea-AI Summary
Biophytis SA (BPTS) Announces Filing for Pre-Submission Meeting with FDA for Emergency Use Authorization of Sarconeos (BIO101) in Severe COVID-19 Cases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.2%
Tags
acquisition covid-19
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.86%
Tags
Rhea-AI Summary
Biophytis and SEQENS have announced a master agreement for the production of the active compound in Sarconeos (BIO101), Biophytis' main drug candidate. SEQENS will produce the active ingredient in France at its Villeneuve La Garenne plant. This partnership is seen as an important step for Biophytis to secure the production of the active ingredient.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
40.72%
Tags
partnership
Biophytis

Nasdaq:BPTS

BPTS Rankings

BPTS Stock Data

3.33M
1.11B
0.05%
0.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
France
Paris

About BPTS

biophytis is a biotech company developping therapeutics for aging diseases. it that has been created in 2006 as a spin-off of université pierre et marie curie (paris). biophytis has developped a portfolio of drug candidates at clinical stage for the treatment of sarcopenic obesity (bio101, bio103) and dry age-related macular degeneration (bio201).